Precision Psychiatry Market is expected to reach $1,727.4 Million by 2026

The healthcare experts have found the precision psychiatry market to be one of the most rapidly evolving and dynamic markets, and the global market for precision psychiatry is predicted to grow at a CAGR of 17.26% over the forecast period of 2021-2026. The market is driven by certain factors, which include decreasing cost of sequencing, increasing adoption of inorganic growth strategies, and global increase in mental health burden, that are fuelling the growth of the global precision psychiatry market.

The BIS Research report on the global precision psychiatry market segments the market on the basis of:

· Product Type (products and services)

· Biomarker (genetic biomarkers and protein biomarkers)

· Sample (blood and non-blood)

· Technology (sequencing, polymerase chain reaction, microarray, immunoassay, liquid chromatography-mass spectrometry, and other technologies)

· Application (Alzheimer’s disease, Parkinson’s disease, autism, depression, schizophrenia, bipolar disorder, and other applications)

· End User (hospitals and diagnostic laboratories, academic and research institutes, and other end users)

· Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World).

Key Questions Answered in this Report:

•   How is precision psychiatry revolutionizing the field of mental health diagnostics?
•   What are the major market drivers, challenges, and opportunities in the global precision psychiatry market?
•   What are the underlying structures resulting in the emerging trends within the global precision psychiatry market?
•   How is the COVID-19 pandemic impacting the global precision psychiatry landscape?
•   What are the key development strategies that are being implemented by the major players in order to sustain in the competitive market?
•   What are the key regulatory implications in developed and developing regions pertaining to precision psychiatry?
•   What are the potential entry barriers, which are expected to be faced by the companies willing to enter a particular region?
•   How is each segment of the market expected to grow during the forecast period from 2021 to 2026, and what is the anticipated revenue to be generated by each of the segments? Following are the segments:
o   Product Type (Products and Services)
o   Sample (Blood-Based and Non-Blood-Based)
o   Biomarker (Genetic Biomarkers and Protein)
o   Technology (Sequencing, PCR, Microarray, Immunoassay, LC/MS, and Others)
o   Application (Parkinson’s Disease, Autism, Alzheimer’s Disease, Depression, Schizophrenia, Bipolar Disorder, and Others)
o   End User (Hospitals and Diagnostic Laboratories, Academic and Research Institutions, and Others)
o   Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)
•   What are the growth opportunities for the companies in the region of their operation?
•   Who are the leading players with significant offerings in the global precision psychiatry market?
•   Which companies are anticipated to be highly disruptive in the future, and why?
•   What are the current unmet needs that are being faced in the global precision psychiatry market?

Request a Sample - https://bisresearch.com/requestsample?id=1086&type=download

Microbiome Therapeutics Market Growth, Segmentation, Opportunity and Forecast to 2032

Global microbiome therapeutics market is expected to grow further in the coming years due to the continuous increase in awareness and need for better and safer treatment alternatives and the dominance of gastrointestinal (GI) and infectious diseases segment can be attributed to the existing dominance of microbiome therapeutics available for a variety of indications ranging from diarrhea and gut dysbiosis to skin disorders, cancer indications among others. The global microbiome therapeutics market which accounted for $306.3 million in 2021 is expected to reach $3,204 million by 2032, reporting a CAGR of 24.95% during the forecast period 2022-2032. The existing microbiome therapeutics market is favored by multiple factors, including the rising geriatric populations coupled with the increasing adoption of inorganic growth strategies by key players in the market. Impact of COVID-19 There were numerous consequences due to the COVID-19 pandemic, especially...

Lung Cancer Genomic Testing Market Industry Structure, Development, Demographics, Demands, Main Players, Innovative Technologies, and Opportunities Till 2031

The shift of healthcare systems toward precision diagnostic and precision medicine will drive the adoption of lung cancer genomic testing facilitating informed treatment decision making and improving healthcare outcomes. Increasing recommendations by the international oncology societies for the use of genomic testing for lung cancer diagnosis provides major opportunities in the global lung cancer genomic testing market. The lung cancer genomic testing medicine market was valued at $1,262.0 million in 2020 and is expected to reach $3,279.8 million by 2031, growing at a CAGR of 8.97% during the forecast period 2021-2031. The growth in the global lung cancer genomic testing market is expected to be driven by increasing awareness and adoption of the lung cancer genomic testing market, recent launches of novel lung cancer genomic testing, and the expanding research in the field of lung cancer with an emphasis on pharmacogenomics and development of companion diagnostics. Im...

Ligase Market Opportunities, Strategies, Share, Segmentation, In-depth Analysis 2032

The global ligase market is progressing rapidly with a significant increase in the research and development activities pertaining to a wide range of ligase product for disease detection, accentuating their criticality in healthcare. Ligase enzyme has a critical role in the molecular diagnostics approach, as it ensures the safe and effective application of targeted therapeutics. Most of the players in the global ligase market offer products encompassing the ligation kits and enzymes. The global ligase market is projected to reach $651.4 million by 2032 from $371.2 million in 2021, at a CAGR of 5.29% during the forecast period 2022-2032. The growth in the global ligase market is expected to be driven by factors such as the increasing prevalence of infectious and genetic diseases on a global level, rising awareness of enzyme based diagnostic testing and significant number of funding for executing research and development. Impact Several techniques are employed in ...

Market Research Reports

Search This Blog